ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

An analysis by Zacks suggests that while ADMA Biologics has shown stronger price performance year-to-date with a 15.9% gain compared to Grifols' 10.6%, Grifols (GRFS) is currently the better investment pick due to its cheaper valuation at 7.19X forward earnings versus ADMA's 25.48X, solid fundamentals, and positive earnings per share estimate revisions for 2025 and 2026; Grifols' 2025 sales are estimated to increase 3.78% year-over-year with EPS improving by 296%.

Analysis

The plasma-derived therapies market features key players ADMA Biologics (ADMA) and Grifols (GRFS), both specializing in immunoglobulin treatments. ADMA Biologics is experiencing robust top-line growth, driven by record demand for its lead product Asceniv in the first quarter, and projects an 18.61% year-over-year sales increase for 2025 with an anticipated 36.73% EPS improvement. Despite this, ADMA's 2025 EPS estimates have seen a recent downward revision, although 2026 estimates have improved, and its R&D pipeline, particularly SG-001, shows potential for $300-500 million in future annual revenues. In contrast, Grifols, one of the top three global producers, reported a 10.3% sales increase to €7.2 billion in 2024 and possesses a more diversified portfolio, including a diagnostics business. For 2025, Grifols' sales are forecast to grow by 3.78%, accompanied by a significant projected EPS surge of 296%, supported by upward estimate revisions for both 2025 and 2026. Year-to-date, ADMA shares have outperformed, gaining 15.9% against GRFS's 10.6%, while the broader industry has declined 4.1%. However, Grifols trades at a considerably more attractive valuation of 7.19X forward earnings, compared to ADMA's 25.48X. This valuation gap, combined with Grifols' established market position, broader product range, positive earnings estimate trends, and a Zacks Rank #2 (Buy) versus ADMA's #3 (Hold), positions Grifols as the comparatively better investment pick according to the analysis.

Key Decisions for Investors

• Investors may find Grifols (GRFS) a more compelling opportunity at current levels, primarily due to its substantially lower forward P/E ratio of 7.19X versus ADMA's 25.48X, coupled with robust projected EPS growth of 296% for 2025 and positive analyst estimate revisions.
• While ADMA Biologics (ADMA) has delivered stronger year-to-date share price appreciation (+15.9%) and projects higher sales growth for 2025 (+18.61%), its premium valuation and recent downward revisions to 2025 EPS estimates suggest a more cautious approach for new investments.
• Consider monitoring key developments for ADMA, such as the clinical progress of its SG-001 pipeline candidate and the sustained market uptake of Asceniv, as these factors could influence its future valuation and investment thesis relative to Grifols.